Leerink Partnrs Brokers Lower Earnings Estimates for BMY

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Research analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Bristol-Myers Squibb in a research note issued to investors on Friday, April 25th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will earn $1.69 per share for the quarter, down from their previous estimate of $1.74. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol-Myers Squibb's Q3 2025 earnings at $1.69 EPS, Q4 2025 earnings at $1.70 EPS, FY2025 earnings at $6.98 EPS, FY2027 earnings at $6.07 EPS, FY2028 earnings at $5.58 EPS and FY2029 earnings at $6.08 EPS.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Bristol-Myers Squibb's revenue was down 5.6% compared to the same quarter last year. During the same quarter last year, the business earned ($4.40) earnings per share.

Several other equities analysts have also recently weighed in on the stock. Piper Sandler began coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective on the stock. Citigroup upped their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. UBS Group dropped their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday. Finally, Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Price Performance

NYSE:BMY traded up $0.75 during trading hours on Monday, reaching $49.21. 19,790,282 shares of the company's stock were exchanged, compared to its average volume of 12,964,894. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The company has a market capitalization of $100.13 billion, a P/E ratio of -11.13, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The business's 50-day simple moving average is $56.24 and its two-hundred day simple moving average is $56.50.

Institutional Trading of Bristol-Myers Squibb

Large investors have recently modified their holdings of the company. Pinney & Scofield Inc. purchased a new stake in Bristol-Myers Squibb during the fourth quarter worth $25,000. Park Square Financial Group LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $26,000. Fairway Wealth LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter valued at approximately $28,000. Transce3nd LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $28,000. Finally, Global Wealth Strategies & Associates increased its position in shares of Bristol-Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 275 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insiders Place Their Bets

In other news, EVP Samit Hirawat acquired 4,250 shares of Bristol-Myers Squibb stock in a transaction on Friday, April 25th. The shares were acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be issued a dividend of $0.62 per share. The ex-dividend date is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.04%. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.